US4226599A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Removal of heparin from heparin-containing blood plasma samples using a triethylaminoethyl cellulose tablet
Assignee: Warner Lambert Co LLC
•
Filing: 1979-06-20
•
Granted: 1980-10-07
•
Expires: 1999-06-20
Abstract
Abstract A tableted form of fibrous triethylaminoethyl cellulose suitable for the removal of heparin from heparin-containing blood plasma. The tablet is composed of granular microcrystalline cellulose and fibrous triethylaminoethyl cellulose in a ratio of from about 5.4:1 to about 10:1. The triethylaminoethyl cellulose tablet, which is formulated to provide from about 5 to about 26 mg. of triethylaminoethyl cellulose per milliliter of plasma sample, is added to a heparin-containing blood plasma sample, the sample is agitated or allowed to stand for a time sufficient to permit adsorption of substantially all heparin present. The sample is then centrifuged and the remaining heparin-free plasma can be subjected to coagulation testing in order to determine the true clotting time.
Inventors
- 👤 James R. Butler
- 👤 James E. Turner
- 👤 Frank W. Goodhart
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-31 03:29
CPC Classifications
G; G01; G01N; G01N33/00; G01N33/48; G01N33/50; G01N33/86; G01N2400/00; G01N2400/10; G01N2400/38; G01N2400/40; Y; Y10; Y10T; Y10T436/00; Y10T436/25; Y10T436/25125
Claims Analysis
Total Claims: 6
Claim 1
Independent Claim
133 words
A method for removing substantially all heparin from a heparin-containing blood plasma test sample which comprises: A. adding to 1 milliliter of plasma sample a diagnostic tablet comprising from about 5.4 to about 10 parts by weight of granular microcrystalline cellulose per part by weight of fibrous triethylaminoethyl cellulose, said tablet being formulated to provide from about 5 to about 26 mg of triethylaminoethyl cellulose per milliliter of plasma sample; B. agitating (A) for a time sufficient to disintegrate the tablet and distribute the fibrous triethylaminoethyl cellulose throughout the plasma sample and permit the adsorption of heparin; C. centrifuging (B) to remove substantially all of the insoluble triethylaminoethyl cellulose heparin complex formed in the plasma sample, together with uncomplexed tablet ingredients; thereby obtaining a substantially heparin-free blood plasma sample suitable for coagulation testing.
Claim 2
Independent Claim
133 words
A method for removing substantially all heparin from a heparin-containing blood plasma test sample which comprises: A. adding to 1 milliliter of plasma sample a diagnostic tablet comprising from about 5.4 to about 10 parts by weight of granular microcrystalline cellulose per part by weight of fibrous triethylaminoethyl cellulose, said tablet being formulated to provide from about 5 to about 26 mg of triethylaminoethyl cellulose per milliliter of plasma sample; B. agitating (A) for a time sufficient to disintegrate the tablet and distribute the fibrous triethylaminoethyl cellulose throughout the plasma sample and permit the adsorption of heparin; C. centrifuging (B) to remove substantially all of the insoluble triethylaminoethyl cellulose heparin complex formed in the plasma sample, together with uncomplexed tablet ingredients; thereby obtaining a substantially heparin-free blood plasma sample suitable for coagulation testing.
Claim 3
Dependent Claim
28 words
A method according to claim 1 wherein, in step (A), the triethylaminoethyl cellulose in the diagnostic tablet has an ion exchange capacity between about 0.3 and 0.8 milliequivalents/gram.
Claim 4
Dependent Claim
28 words
A method according to claim 1 wherein, in step (A), the triethylaminoethyl cellulose in the diagnostic tablet has an ion exchange capacity between about 0.5 and 0.62 milliequivalents/grams.
Claim 5
Dependent Claim
43 words
A method according to claim 1 wherein, in step (B), the sample is agitated vigorously to disintegrate the tablet and then agitated gently to maintain the fibrous triethylaminoethyl cellulose distributed throughout the plasma sample for a time sufficient to permit adsorption of heparin.
Claim 6
Dependent Claim
33 words
A method according to claim 1 wherein, in step (C), the sample is agitated vigorously to disintegrate the tablet and then allowed to stand for a time sufficient to permit adsorption of heparin.
References Cited (Backward Citations)
US2128432A
Cited
US2687990A
Cited
US3099600A
Cited
DE1195010B
Cited
US4055510A
Cited
US4122250A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1983-10-07 | 1984-04-07 | 1984-10-07 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1987-10-07 | 1988-04-07 | 1988-10-07 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1991-10-07 | 1992-04-07 | 1992-10-07 | $7700.00 | Window Closed / Lapsed |